Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.

Hersey S, Celik H, Rosen S, Scott C, Keeling P, Joglekar L, Lawler M.

Open source

DOI
10.1016/j.ejca.2026.117009
Published
2026-08-25
Container
Eur J Cancer
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2026.117009,
  title = {Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.},
  author = {Hersey S and  Celik H and  Rosen S and  Scott C and  Keeling P and  Joglekar L and  Lawler M.},
  year = {2026},
  journal = {Eur J Cancer},
  doi = {10.1016/j.ejca.2026.117009},
  url = {https://doi.org/10.1016/j.ejca.2026.117009}
}

RIS

TY  - JOUR
TI  - Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.
AU  - Hersey S
AU  -  Celik H
AU  -  Rosen S
AU  -  Scott C
AU  -  Keeling P
AU  -  Joglekar L
AU  -  Lawler M.
PY  - 2026
JO  - Eur J Cancer
DO  - 10.1016/j.ejca.2026.117009
UR  - https://doi.org/10.1016/j.ejca.2026.117009
ER  - 

APA

S, H., H, C., S, R., C, S., P, K., L, J., & M., L. (2026). Diagnostic regulatory pathways are an underrecognized bottleneck in precision oncology clinical trials: Real-world evidence across Europe.. Eur J Cancer. https://doi.org/10.1016/j.ejca.2026.117009

Source records